Sector Update: Healthcare

By
A A A
Share |

Healthcare shares are flat in pre-market trade. In earnings news, Endo Health Solutions ( ENDP ) reported Q2 earnings of $1.42 per share, ex one-time items, versus the Capital IQ consensus of $1.15. Revenues were $766.6 million, versus the analyst estimate of $721.61 million.

The company now expects FY13 EPS of $4.25 - $4.55, ex non-recurring items, down from the previous guidance range of $4.40 - $4.70 and compared with the Street view of $4.33. Revenues are now expected to be $2.7 billion - 2.8 billion, down from the prior guidance of $2.80 billion - $2.95 billion. Analysts are looking for revenues of $2.75 billion.

ENDP shares closed at $38.71 with a 52-week range of $25.00 - $39.90.

And, Regeneron Pharmaceuticals Inc. ( REGN ) reported Q2 2013 non-GAAP net income of $198 million, or $1.73 per diluted share, on revenues of $458 million. Analysts expected revenues of $473.2 million and GAAP earnings per share of $0.88, if comparable.

In the same period last year, non-GAAP net income was $102 million, or $0.90 per diluted share, on revenues of $304 million. REGN is down 3.5% at $261.50.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: ENDP , REGN

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

Most Active by Volume

89,970,926
  • $16.15 ▲ 0.12%
77,131,582
  • $58.94 ▼ 1.31%
67,336,935
  • $26.56 ▲ 1.68%
48,814,124
  • $86.20 ▲ 0.02%
47,526,126
  • $23.21 ▲ 0.78%
44,660,424
  • $23.91 ▲ 6.36%
38,799,699
  • $4.289 ▲ 4.36%
36,199,890
  • $40.01 ▼ 0.97%
As of 4/17/2014, 04:07 PM